AU2020272973B2 - Novel synthetic options towards the manufacture of (6R,10S)-10- {4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6H)-one - Google Patents

Novel synthetic options towards the manufacture of (6R,10S)-10- {4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6H)-one

Info

Publication number
AU2020272973B2
AU2020272973B2 AU2020272973A AU2020272973A AU2020272973B2 AU 2020272973 B2 AU2020272973 B2 AU 2020272973B2 AU 2020272973 A AU2020272973 A AU 2020272973A AU 2020272973 A AU2020272973 A AU 2020272973A AU 2020272973 B2 AU2020272973 B2 AU 2020272973B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
acid
yield
sep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020272973A
Other languages
English (en)
Other versions
AU2020272973A1 (en
Inventor
Cyril BEN ΗΑΪΜ
Diego Fernando Domenico BROGGINI
Duy Chi Trung CAO
Kostiantyn CHERNICHENKO
Nicolas Cuniere
Yu Fan
Sergei KOLOTUCHIN
Sébastien François Emmanuel LEMAIRE
Subha MUKHERJEE
Eric M. SIMMONS
Amarjit Singh
Simon Albert WAGSCHAL
Carolyn S. WEI
Yi Xiao
Changxia YUAN
Bin Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Original Assignee
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Bristol Myers Squibb Co filed Critical Janssen Pharmaceutica NV
Publication of AU2020272973A1 publication Critical patent/AU2020272973A1/en
Application granted granted Critical
Publication of AU2020272973B2 publication Critical patent/AU2020272973B2/en
Priority to AU2026201396A priority Critical patent/AU2026201396A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020272973A 2019-04-11 2020-04-10 Novel synthetic options towards the manufacture of (6R,10S)-10- {4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6H)-one Active AU2020272973B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201396A AU2026201396A1 (en) 2019-04-11 2026-02-25 Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832614P 2019-04-11 2019-04-11
US62/832,614 2019-04-11
PCT/US2020/027655 WO2020210613A1 (en) 2019-04-11 2020-04-10 Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201396A Division AU2026201396A1 (en) 2019-04-11 2026-02-25 Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one

Publications (2)

Publication Number Publication Date
AU2020272973A1 AU2020272973A1 (en) 2021-12-02
AU2020272973B2 true AU2020272973B2 (en) 2025-11-27

Family

ID=70457148

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020272973A Active AU2020272973B2 (en) 2019-04-11 2020-04-10 Novel synthetic options towards the manufacture of (6R,10S)-10- {4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6H)-one
AU2026201396A Pending AU2026201396A1 (en) 2019-04-11 2026-02-25 Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201396A Pending AU2026201396A1 (en) 2019-04-11 2026-02-25 Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one

Country Status (16)

Country Link
US (2) US12378246B2 (cg-RX-API-DMAC7.html)
EP (2) EP4234555A3 (cg-RX-API-DMAC7.html)
JP (2) JP7631218B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260047658A (cg-RX-API-DMAC7.html)
CN (2) CN114375290B (cg-RX-API-DMAC7.html)
AR (1) AR118649A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020272973B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020368A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132365A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192807A1 (cg-RX-API-DMAC7.html)
ES (1) ES2969253T3 (cg-RX-API-DMAC7.html)
IL (1) IL287102B2 (cg-RX-API-DMAC7.html)
MX (2) MX2025014306A (cg-RX-API-DMAC7.html)
SG (1) SG11202111132WA (cg-RX-API-DMAC7.html)
TW (1) TWI880924B (cg-RX-API-DMAC7.html)
WO (1) WO2020210613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11788071B2 (en) 2020-04-10 2023-10-17 Codexis, Inc. Engineered transaminase polypeptides
EP4225757A1 (en) * 2020-10-12 2023-08-16 Bristol-Myers Squibb Company A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3293186A1 (en) * 2014-10-01 2018-03-14 Bristol-Myers Squibb Company Pyrimidinones as factor xia inhibitors
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CN105294496A (zh) 2015-09-28 2016-02-03 中山大学 一种西酞普兰中间体的制备方法
CN113677682B (zh) 2019-04-16 2023-05-30 华润生物医药有限公司 作为XIa因子抑制剂的大环衍生物
WO2021013209A1 (zh) 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CA3179679A1 (en) 2020-04-10 2021-10-14 Codexis, Inc. Carboxyesterase polypeptides for kinetic resolution

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3293186A1 (en) * 2014-10-01 2018-03-14 Bristol-Myers Squibb Company Pyrimidinones as factor xia inhibitors
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途

Also Published As

Publication number Publication date
MX2021012286A (es) 2022-04-06
BR112021020368A2 (pt) 2021-12-07
JP2025084766A (ja) 2025-06-03
US20260092066A1 (en) 2026-04-02
KR20220045105A (ko) 2022-04-12
TW202104188A (zh) 2021-02-01
CA3132365A1 (en) 2020-10-15
JP2022526659A (ja) 2022-05-25
US12378246B2 (en) 2025-08-05
EP3953334A1 (en) 2022-02-16
MX2025014306A (es) 2026-01-07
IL287102B2 (en) 2025-12-01
AR118649A1 (es) 2021-10-20
WO2020210613A1 (en) 2020-10-15
EP4234555A2 (en) 2023-08-30
AU2026201396A1 (en) 2026-03-19
TWI880924B (zh) 2025-04-21
IL287102B1 (en) 2025-08-01
EA202192807A1 (ru) 2022-02-24
CN119775276A (zh) 2025-04-08
US20220144836A1 (en) 2022-05-12
IL287102A (en) 2021-12-01
SG11202111132WA (en) 2021-11-29
CN114375290A (zh) 2022-04-19
AU2020272973A1 (en) 2021-12-02
KR20260047658A (ko) 2026-04-08
KR102929951B1 (ko) 2026-02-24
EP3953334B1 (en) 2023-11-22
CN114375290B (zh) 2024-11-29
EP4234555A3 (en) 2024-01-03
JP7885383B2 (ja) 2026-07-06
JP7631218B2 (ja) 2025-02-18
ES2969253T3 (es) 2024-05-17

Similar Documents

Publication Publication Date Title
Kozikowski et al. Synthesis of huperzine A, its analogs, and their anticholinesterase activity
AU2026201396A1 (en) Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
Alcaide et al. Stereoselective preparation of mono-and bis-. beta.-lactams by the 1, 4-diaza-1, 3-diene-acid chloride condensation: scope and synthetic applications
ZA200601055B (en) Regioselective synthesis of CCI-779
EP3676270A1 (en) Macrocyclic compounds that inhibit mcl-1 protein
EP3753926B1 (en) Spiro compound as indoleamine-2,3-dioxygenase inhibitor
CA3195024A1 (en) A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one
Langlois et al. Creation of quaternary stereocentres: synthesis of new polyhydroxylated indolizidines
WO2002022618A1 (fr) Preparation de la camptothecine et de ses derives
EA050867B1 (ru) СПОСОБ ПОЛУЧЕНИЯ (6R,10S)-10-{4-[5-ХЛОРО-2-(4-ХЛОРО-1Н-1,2,3-ТРИАЗОЛ-1-ИЛ)ФЕНИЛ]-6-ОКСО-1(6Н)-ПИРИМИДИНИЛ}-1-(ДИФТОРОМЕТИЛ)-6-МЕТИЛ-1,4,7,8,9,10-ГЕКСАГИДРО-11,15-(МЕТЕНО)ПИРАЗОЛО[4,3-b][1,7]ДИАЗАЦИКЛОТЕТРАДЕЦИН-5(6Н)-ОНА
US5262425A (en) α-mannosidase inhibitors
AU2014229065A1 (en) Methods of synthesizing a difluorolactam analog
CS354591A3 (en) Aminodiole derivatives, process of their preparation and their use
CN117088847B (zh) 一种并环化合物的制备、应用及用途
HK40124045A (en) Novel synthetic options towards the manufacture of a compound
CN103288871A (zh) 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
Andrei et al. Rh (II)-carbenoid insertion into chiron substrates for stereoselective amino acid construction
WO2023187670A1 (en) Diazabicyclooctane derivatives useful as matrix metalloproteinase inhibitors
US5952376A (en) Trienyl compounds
Hájíček et al. Stereospecific total synthesis of (+)-18-methylenevincadifformine
JP2003183277A (ja) エピヒマンドラビン誘導体
JPH01268684A (ja) アセチレン性、トリイン環状カーボネート
HK1085482B (en) Regioselective synthesis of cci-779

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)